ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Deflecting Earmarks, NCI Advisors Lay Out Research Opportunities In Breast, Prostate

February 26, 1999

Partnership Points to New Path Forward For Drug Approval and Clinical Research

June 20, 2014

Additional DCE Contract Concepts

November 16, 1984

Wyden Compared Taxol To AZT; But Experts Note Lack Of Patent

August 9, 1991

Cancer Centers Form Network To Compete For Managed Care, Develop Standards

January 27, 1995

NCI Producing TV Tapes For Black Awareness Program

March 14, 1986